Semler Scientific (SMLR) gets buying a rating from Benchmark, $ 101 target at Bitcoin Treasury Pivot
Benchmark’s Mark Palmer started the scientific semler scope (Smlr) with a purchase rating and a target price of $ 101, citing company’s dramatic pivot from medical diagnostics to bitcoin
accumulation as a major value driver.
Semler, who spent more than 15 years focused on acute discovery of the disease, Adopted Bitcoin As the main owner of the Treasury Reserve in May last year.
Moving made only the second firm listed in the US, after Michael Saylor’s approach (Mstr)to adopt Bitcoin as a Treasury reserve.
Since then, the company has gained about 4,636 BTCs for $ 430 million, with an average cost of $ 92,753 per Bitcoin, the report said.
Palmer noted that the stock rallied 178% in six and a half months following the announcement of its Bitcoin standard, which was peering for $ 81.56 in December 2024. However, analyst that semler was still trading in a steep discount compared to Bitcoin’s treasury.
The multiple amount of net asset (MNAV) Sit at 1.25, compared to 4.29 for Japan -based metaplanet (3350) and 6.45 for the French blockchain group (ALTBG)mentioned by the analyst.
The benchmark believes that this space can close. Management recently appointed Joe Burnett as director of the Bitcoin Strategy and outlined by the Bold BTC Accumulation Target: 10,000 BTC by the end of 2025, 42,000 at the end of 2026, and 105,000 by the end of 2027.
The report records that resolving legal and regulations headwind from the semler’s health care business, including a Department of Justice (DOJ) Investigation and uncertainty in Medicare’s repayment, can help lift its appreciation.
Benchmark’s target price of $ 101 is based on a sum of appreciation in total assuming that Bitcoin will hit $ 225,000 by the end of the year 2026.
Read more: Semler Scientific Trades in Premium to Bitcoin Holdings for the first time in three weeks
